File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation
  • Basic View
  • Metadata View
  • XML View
TitleEntecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation
 
AuthorsFung, JYY1
Cheung, C1
Chan, SC1 1
Yuen, MF1 1
Chok, KSH1
Sharr, W1
Dai, WC
Chan, ACY1
Cheung, TT
Tsang, S1
Lam, B1
Lai, CL1 1
Lo, CM1 1
 
Issue Date2011
 
PublisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/gastro
 
CitationGastroenterology, 2011, v. 141 n. 4, p. 1212-1219 [How to Cite?]
DOI: http://dx.doi.org/10.1053/j.gastro.2011.06.083
 
AbstractBACKGROUND and AIMS: We investigated the efficacy of entecavir, a cyclopentyl guanosine nucleoside analogue, as monoprophylaxis in patients with chronic hepatitis B who received a liver transplant. METHODS: We studied data from 80 consecutive patients who received a liver transplant (47 from living donors and 33 from deceased donors) for hepatitis B-related disease and entecavir monotherapy as prophylaxis. None of the patients received hepatitis B immunoglobulin. Indications for transplant included decompensation from cirrhosis (27.5%), acute-on-chronic hepatitis B (47.5%), and hepatocellular carcinoma (25%). The median follow-up time was 26 months (range, 5-40 months). Before transplant, 33 patients were not on antiviral therapy and 47 were on oral therapy (18 had received less than 3 months of treatment). RESULTS: At the time of transplant, the median log HBV DNA level was 3.5 copies/mL (range, 1.54-8.81); 21 patients (26%) had undetectable levels of HBV DNA. The cumulative rate of hepatitis B surface antigen (HBsAg) loss was 86% and 91% after 1 and 2 years, respectively. Ten patients had reappearance of HBsAg. Eighteen patients (22.5%) were HBsAg positive at the time of their last examination; 17 of these had undetectable levels of HBV DNA, and the remaining patient had a low level of HBV DNA (217 copies/mL). There was no evidence of mutations at sites that confer resistance to entecavir among patients who were HBsAg positive. CONCLUSIONS: Although only 26% of patients had complete viral suppression at the time of transplant, 91% lost HBsAg, with 98.8% achieving undetectable levels of HBV DNA. A hepatitis B immunoglobulin-free regimen of entecavir monotherapy is effective after liver transplantation for chronic hepatitis B.
 
ISSN0016-5085
2012 Impact Factor: 12.821
2012 SCImago Journal Rankings: 3.649
 
DOIhttp://dx.doi.org/10.1053/j.gastro.2011.06.083
 
ISI Accession Number IDWOS:000295593700028
Funding AgencyGrant Number
Bristol-Myers Squibb
Funding Information:

The authors disclose the following: Man-Fung Yuen has received speakers' bureau and research grants from Bristol-Myers Squibb. Ching-Lung Lai and James Fung have been invited speakers for Bristol-Myers Squibb. The remaining authors disclose no conflicts.

 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorFung, JYY
 
dc.contributor.authorCheung, C
 
dc.contributor.authorChan, SC
 
dc.contributor.authorYuen, MF
 
dc.contributor.authorChok, KSH
 
dc.contributor.authorSharr, W
 
dc.contributor.authorDai, WC
 
dc.contributor.authorChan, ACY
 
dc.contributor.authorCheung, TT
 
dc.contributor.authorTsang, S
 
dc.contributor.authorLam, B
 
dc.contributor.authorLai, CL
 
dc.contributor.authorLo, CM
 
dc.date.accessioned2011-08-26T14:24:07Z
 
dc.date.available2011-08-26T14:24:07Z
 
dc.date.issued2011
 
dc.description.abstractBACKGROUND and AIMS: We investigated the efficacy of entecavir, a cyclopentyl guanosine nucleoside analogue, as monoprophylaxis in patients with chronic hepatitis B who received a liver transplant. METHODS: We studied data from 80 consecutive patients who received a liver transplant (47 from living donors and 33 from deceased donors) for hepatitis B-related disease and entecavir monotherapy as prophylaxis. None of the patients received hepatitis B immunoglobulin. Indications for transplant included decompensation from cirrhosis (27.5%), acute-on-chronic hepatitis B (47.5%), and hepatocellular carcinoma (25%). The median follow-up time was 26 months (range, 5-40 months). Before transplant, 33 patients were not on antiviral therapy and 47 were on oral therapy (18 had received less than 3 months of treatment). RESULTS: At the time of transplant, the median log HBV DNA level was 3.5 copies/mL (range, 1.54-8.81); 21 patients (26%) had undetectable levels of HBV DNA. The cumulative rate of hepatitis B surface antigen (HBsAg) loss was 86% and 91% after 1 and 2 years, respectively. Ten patients had reappearance of HBsAg. Eighteen patients (22.5%) were HBsAg positive at the time of their last examination; 17 of these had undetectable levels of HBV DNA, and the remaining patient had a low level of HBV DNA (217 copies/mL). There was no evidence of mutations at sites that confer resistance to entecavir among patients who were HBsAg positive. CONCLUSIONS: Although only 26% of patients had complete viral suppression at the time of transplant, 91% lost HBsAg, with 98.8% achieving undetectable levels of HBV DNA. A hepatitis B immunoglobulin-free regimen of entecavir monotherapy is effective after liver transplantation for chronic hepatitis B.
 
dc.description.natureLink_to_subscribed_fulltext
 
dc.identifier.citationGastroenterology, 2011, v. 141 n. 4, p. 1212-1219 [How to Cite?]
DOI: http://dx.doi.org/10.1053/j.gastro.2011.06.083
 
dc.identifier.doihttp://dx.doi.org/10.1053/j.gastro.2011.06.083
 
dc.identifier.eissn1528-0012
 
dc.identifier.epage1219
 
dc.identifier.hkuros192486
 
dc.identifier.hkuros189826
 
dc.identifier.isiWOS:000295593700028
Funding AgencyGrant Number
Bristol-Myers Squibb
Funding Information:

The authors disclose the following: Man-Fung Yuen has received speakers' bureau and research grants from Bristol-Myers Squibb. Ching-Lung Lai and James Fung have been invited speakers for Bristol-Myers Squibb. The remaining authors disclose no conflicts.

 
dc.identifier.issn0016-5085
2012 Impact Factor: 12.821
2012 SCImago Journal Rankings: 3.649
 
dc.identifier.issue4
 
dc.identifier.openurl
 
dc.identifier.pmid21762659
 
dc.identifier.scopuseid_2-s2.0-80053583302
 
dc.identifier.spage1212
 
dc.identifier.urihttp://hdl.handle.net/10722/137375
 
dc.identifier.volume141
 
dc.languageeng
 
dc.publisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/gastro
 
dc.publisher.placeUnited States
 
dc.relation.ispartofGastroenterology
 
dc.relation.referencesReferences in Scopus
 
dc.subject.meshAntiviral Agents - adverse effects - therapeutic use
 
dc.subject.meshCarcinoma, Hepatocellular - surgery - virology
 
dc.subject.meshGuanine - adverse effects - analogs and derivatives - therapeutic use
 
dc.subject.meshHepatitis B, Chronic - complications - diagnosis - drug therapy - surgery
 
dc.subject.meshLiver Cirrhosis - surgery - virology
 
dc.titleEntecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Fung, JYY</contributor.author>
<contributor.author>Cheung, C</contributor.author>
<contributor.author>Chan, SC</contributor.author>
<contributor.author>Yuen, MF</contributor.author>
<contributor.author>Chok, KSH</contributor.author>
<contributor.author>Sharr, W</contributor.author>
<contributor.author>Dai, WC</contributor.author>
<contributor.author>Chan, ACY</contributor.author>
<contributor.author>Cheung, TT</contributor.author>
<contributor.author>Tsang, S</contributor.author>
<contributor.author>Lam, B</contributor.author>
<contributor.author>Lai, CL</contributor.author>
<contributor.author>Lo, CM</contributor.author>
<date.accessioned>2011-08-26T14:24:07Z</date.accessioned>
<date.available>2011-08-26T14:24:07Z</date.available>
<date.issued>2011</date.issued>
<identifier.citation>Gastroenterology, 2011, v. 141 n. 4, p. 1212-1219</identifier.citation>
<identifier.issn>0016-5085</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/137375</identifier.uri>
<description.abstract>BACKGROUND and AIMS: We investigated the efficacy of entecavir, a cyclopentyl guanosine nucleoside analogue, as monoprophylaxis in patients with chronic hepatitis B who received a liver transplant. METHODS: We studied data from 80 consecutive patients who received a liver transplant (47 from living donors and 33 from deceased donors) for hepatitis B-related disease and entecavir monotherapy as prophylaxis. None of the patients received hepatitis B immunoglobulin. Indications for transplant included decompensation from cirrhosis (27.5%), acute-on-chronic hepatitis B (47.5%), and hepatocellular carcinoma (25%). The median follow-up time was 26 months (range, 5-40 months). Before transplant, 33 patients were not on antiviral therapy and 47 were on oral therapy (18 had received less than 3 months of treatment). RESULTS: At the time of transplant, the median log HBV DNA level was 3.5 copies/mL (range, 1.54-8.81); 21 patients (26%) had undetectable levels of HBV DNA. The cumulative rate of hepatitis B surface antigen (HBsAg) loss was 86% and 91% after 1 and 2 years, respectively. Ten patients had reappearance of HBsAg. Eighteen patients (22.5%) were HBsAg positive at the time of their last examination; 17 of these had undetectable levels of HBV DNA, and the remaining patient had a low level of HBV DNA (217 copies/mL). There was no evidence of mutations at sites that confer resistance to entecavir among patients who were HBsAg positive. CONCLUSIONS: Although only 26% of patients had complete viral suppression at the time of transplant, 91% lost HBsAg, with 98.8% achieving undetectable levels of HBV DNA. A hepatitis B immunoglobulin-free regimen of entecavir monotherapy is effective after liver transplantation for chronic hepatitis B.</description.abstract>
<language>eng</language>
<publisher>WB Saunders Co. The Journal&apos;s web site is located at http://www.elsevier.com/locate/gastro</publisher>
<relation.ispartof>Gastroenterology</relation.ispartof>
<subject.mesh>Antiviral Agents - adverse effects - therapeutic use</subject.mesh>
<subject.mesh>Carcinoma, Hepatocellular - surgery - virology</subject.mesh>
<subject.mesh>Guanine - adverse effects - analogs and derivatives - therapeutic use</subject.mesh>
<subject.mesh>Hepatitis B, Chronic - complications - diagnosis - drug therapy - surgery</subject.mesh>
<subject.mesh>Liver Cirrhosis - surgery - virology</subject.mesh>
<title>Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=0016-5085&amp;volume=141&amp;issue=4&amp;spage=1212&amp;epage=1219&amp;date=2011&amp;atitle=Entecavir+monotherapy+is+effective+in+suppressing+hepatitis+B+virus+after+liver+transplantation</identifier.openurl>
<description.nature>Link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1053/j.gastro.2011.06.083</identifier.doi>
<identifier.pmid>21762659</identifier.pmid>
<identifier.scopus>eid_2-s2.0-80053583302</identifier.scopus>
<identifier.hkuros>192486</identifier.hkuros>
<identifier.hkuros>189826</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-80053583302&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>141</identifier.volume>
<identifier.issue>4</identifier.issue>
<identifier.spage>1212</identifier.spage>
<identifier.epage>1219</identifier.epage>
<identifier.eissn>1528-0012</identifier.eissn>
<identifier.isi>WOS:000295593700028</identifier.isi>
<publisher.place>United States</publisher.place>
</item>
Author Affiliations
  1. The University of Hong Kong